Business Context and Reporting Period
This Form 8-K filing by AngioDynamics, Inc. (NASDAQ: ANGO) reports a corporate governance event dated May 31, 2019. The filing was signed on June 6, 2019, by Stephen A. Trowbridge, Senior Vice President and General Counsel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the departure of a senior executive:
- Executive: Robert A. Simpson, Senior Vice President and General Manager for Vascular Interventions and Therapies.
- Effective Date: August 31, 2019.
- Reason: Pursuing other opportunities.
Management Commentary and Contingencies
As part of the departure agreement, Mr. Simpson will receive severance payments equal to the continuation of his annual base salary for a period of 12 months. This compensation is contingent upon the execution of a waiver and general release of claims in favor of the Company.
Investor Verification Checklist
- Verify the impact of Mr. Simpson's departure on the Vascular Interventions and Therapies division.
- Confirm the timeline for the appointment of a replacement for the Senior Vice President role.
- Review the Company's subsequent filings for any updates on the transition plan or additional executive departures.